Gilead's Sovaldi and velpatasvir combination achieves high rates of virologic response at 12 weeks
US biotech major Gilead Sciences (Nasdaq: GILD) has reported high rates of virologic response at 12 weeks across all six genotypes of hepatitis C in trials of its drug Sovaldi (sofosbuvir) and velpatasvir.
The ASTRAL-1, ASTRAL-2 and ASTRAL-3 studies consisted of 1,035 patients with hepatitis C infection who received treatment with Sovaldi and velpatasvir for 12 weeks. The company found that 21% of the patients in the trials had compensated cirrhosis, and 28% had failed prior treatments.
Norbert Bischofberger, executive vice president of R&D and chief scientific officer at Gilead, said that the results from the ASTRAL studies "demonstrate that a 12-week course of therapy with the first fixed-dose combination of two pan-genotypic compounds can provide high cure rates for patients with all HCV genotypes."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze